期刊文献+

基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析 被引量:2

Expression of microRNA-324-5p in hepatocellular carcinoma based on the Cancer Genome Atlas(TCGA)database and analysis of prognosis risk factor
下载PDF
导出
摘要 目的:探究microRNA-324-5p(miR-324-5p)在肝细胞癌(hepatocellular carcinoma,HCC)组织中的表达与病人预后危险因素。方法:通过TCGA(The Cancer Genome Atlas)数据库获得的肿瘤组织和正常肝组织miRNA表达谱数据与病人临床信息,分析miR-324-5p表达差异与病理的关系。通过绘制生存曲线分析miR-324-5p表达与病人预后的相关性。单因素和多因素Cox回归模型分析HCC相关危险因素。结果:miR-324-5p在HCC表达高于正常组织(P<0.001),且与不良预后相关。多因素Cox分析表明miR-324-5p可作为HCC预后不良的独立危险因素(P<0.05)。结论:miR-324-5p在HCC组织过表达,是HCC病人总生存期缩短的独立危险因素,为HCC预后判断的潜在生物学标志物。 Objective To study the expression of microRNA-324-5p(miR-324-5p)in hepatocellular carcinoma(HCC) and the prognosis risk factor in patients with HCC.Methods MiRNA expression database in tissue of both tumor and normal liver combined with clinical data of HCC patients were collected from The Cancer Genome Atlas(TCGA)database.Relationship between miR-324-5p expression and pathological features was analyzed.Relation of miR-324-5p expression to prognosis of the patients was analyzed through survival curve.Univariate and multivariate Cox regression models were used to analyze the risk factors related to HCC.Results The expressions of miR-324-5p in HCC were higher than those in normal tissues(P<0.001)and were associated with poor prognosis.Multivariate Cox analysis showed that miR-324-5p was an independent risk factor for HCC(P<0.05).Conclusions MiR-324-5p is upregulated in HCC,which play a role as risk factor in the HCC patients with shorten suvival and may be a possible biomarker of HCC prognosis prediction.
作者 吴城孝 方婕 周霁川 肖永胜 张晓光 WU Chengxiao;FANG Jie;ZHOU Jichuan;XIAO Yongsheng;ZHANG Xiaoguang(Department of Anesthesiology,Jinshan Hospital,Fudan University,Shanghai 201508,China;Department of Anesthesiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Liver Oncology Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《外科理论与实践》 2021年第3期249-253,共5页 Journal of Surgery Concepts & Practice
关键词 肝细胞癌 microRNA-324-5p 生物学标志物 Hepatocellular carcinoma MicroRNA-324-5p Biomarker
  • 相关文献

参考文献2

二级参考文献121

  • 1Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, MinerJN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2inhibitor refametinib (BAY 86-9766) in combination with sorafenibexhibits antitumor activity in preclinical murine and rat models ofhepatocellular carcinoma. Neoplasia 2013; 15: 1161-1171 [PMID:24204195 DOI: 10.1593/neo.13812]. 被引量:1
  • 2Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT,Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation inhepatocellular carcinoma. Neoplasia 2014; 16: 595-605 [PMID:25047655 DOI: 10.1016/j.neo.2014.06.005]. 被引量:1
  • 3Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelialmesenchymaltransition targets PTEN and SMAD7 to promotedrug resistance and recurrence of liver cancer. Hepatology 2013;58: 629-641 [PMID: 23471579 DOI: 10.1002/hep.26369]. 被引量:1
  • 4El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiologyand molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]. 被引量:1
  • 5Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, SekiE, Karin M. p38α inhibits liver fibrogenesis and consequenthepatocarcinogenesis by curtailing accumulation of reactiveoxygen species. Cancer Res 2013; 73: 215-224 [PMID: 23271722DOI: 10.1158/0008-5472.can-12-1602]. 被引量:1
  • 6Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, Gao Y, ZhangS, Lu Z, Ye L, Zhang X. Hepatitis B virus X protein inhibitstumor suppressor miR-205 through inducing hypermethylation ofmiR-205 promoter to enhance carcinogenesis. Neoplasia 2013; 15:1282-1291 [PMID: 24339740 DOI: 10.1593/neo.131362]. 被引量:1
  • 7Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, PengT, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellularcarcinoma from Guangxi, China : role of chronic hepatitis B virusinfection and aflatoxin B1 exposure. Liver Int 2015; 35: 999-1009[PMID: 24461059 DOI: 10.1111/liv.12460]. 被引量:1
  • 8Aravalli RN, Cressman EN, Steer CJ. Cellular and molecularmechanisms of hepatocellular carcinoma: an update. ArchToxicol 2013; 87: 227-247 [PMID: 23007558 DOI: 10.1007/s00204-012-0931-2]. 被引量:1
  • 9Shin JW, Chung YH. Molecular targeted therapy for hepatocellularcarcinoma: current and future. World J Gastroenterol 2013; 19:6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144]. 被引量:1
  • 10Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. Thelong intergenic noncoding RNA UFC1, a target of MicroRNA 34a,interacts with the mRNA stabilizing protein HuR to increase levelsof β-catenin in HCC cells. Gastroenterology 2015; 148: 415-426.e18 [PMID: 25449213 DOI: 10.1053/j.gastro.2014.10.012]. 被引量:1

共引文献3412

同被引文献23

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部